Larry L. Wood - 10 Aug 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, TAVR
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
10 Aug 2021
Net transactions value
-$618,088
Form type
4
Filing time
10 Aug 2021, 21:24:30 UTC
Previous filing
12 Jul 2021
Next filing
10 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $275,590 +7,830 +2.1% $35.20 379,964 10 Aug 2021 Direct F1
transaction EW Common Stock Sale $893,678 -7,830 -2.1% $114.14 372,134 10 Aug 2021 Direct F1, F2
holding EW Common Stock 496 10 Aug 2021 401(k) F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -7,830 -20% $0.000000 31,320 10 Aug 2021 Common Stock 7,830 $35.20 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 29, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $113.7250 to $114.4400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.